Nuvig Therapeutics

About Nuvig Therapeutics

Nuvig Therapeutics is dedicated to changing the treatment paradigm for patients with autoimmune diseases by developing next-generation immune modulators that address underlying inflammatory conditions without compromising immune function.

Products & Services

NVG-2089:A next-generation immune modulator currently in Phase 2 clinical trials for CIDP (Chronic Inflammatory Demyelinating Polyneuropathy).

Novel Immunomodulators:Innovative therapies focusing on resolving autoimmune dysregulation through endogenous regulatory mechanisms.

Specialties

Autoimmune Disease Therapies Immune Modulation Chronic Inflammatory Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 161000000 MR: - FA: 161 million FAN: 161000000	D: 2024-12-05 FD: 2024-12-05	14 investors

Series B Latest

2024-12-05

$161.0M

14 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David J. Woodhouse

Chief Executive Officer

P

Pamela Conley

Cofounder & Chief Scientific Officer

A

Alan Glicklich

Chief Medical Officer

G

Greg Coffey

Cofounder & Vice President, Immunology & Clinical Translational Research

B

Bella Oguno

Vice President, Development Operations

B

Bill Avery

Vice President, Nonclinical Development

View 24 more team members with Pro

Unlock Full Team Directory

Recent News